ABBV data provided by YCharts. Despite facing challenges, AbbVie remains active in mergers and acquisitions. Recently, the company completed its acquisition of Aliada Therapeutics for $1.4 billion in cash, gaining access to a promising Alzheimer’s disease candidate. Additionally, AbbVie announced the acquisition of Nimble Therapeutics for $200 million, which brings a pipeline of immunology candidates.
Following the patent cliff of its former top-selling medicine Humira, AbbVie continues to grow its revenue. Key contributors to revenue growth are immunology drugs Skyrizi and Rinvoq, which saw significant sales increases in the third quarter. These drugs are expected to drive growth into the next decade.
AbbVie is also focused on launching new products and has a robust pipeline with numerous ongoing programs. As a Dividend King, AbbVie has a strong track record of dividend increases, with a current yield of around 3.8%.
Moving on to Amgen, the company recently faced a setback with its weight loss candidate MariTide. While the phase 2 results were positive, they were not deemed strong enough to compete with current leaders in the market. Nonetheless, Amgen does not need to capture a significant market share to be successful in the growing weight loss arena projected to reach $150 billion by the early 2030s.
Amgen’s revenue grew by 23% in the third quarter, partly attributed to the acquisition of Horizon Therapeutics. The company now owns Tepezza, the only FDA-approved medicine for thyroid eye disease. Amgen’s Tezspire, developed in collaboration with AstraZeneca for asthma, is also showing promising results.
Despite the less-than-stellar phase 2 data for MariTide, Amgen’s diverse portfolio and strategic acquisitions position it for continued growth. The company’s dividend remains stable, and it is well-positioned to capitalize on opportunities in its pipeline and expanding markets.
The stock market has seen a surge of 201% over the past decade, with a current forward yield of approximately 3.7%. This makes it an attractive opportunity for investors looking to capitalize on dividend growth stocks. It is advisable not to overlook the potential gains that this particular stock could offer in the long term.
For those who may have regrets about missing out on the chance to invest in top-performing stocks, a second opportunity may be on the horizon. Occasionally, a team of seasoned analysts will identify companies with significant growth potential and issue a “Double Down” stock recommendation. This signals a belief that these companies are poised for substantial growth in the near future. If concerns linger about having missed the initial investment window, now could be the optimal moment to consider entering the market before it becomes too late. And the historical data reinforces the validity of this strategy:
– Nvidia: A $1,000 investment following the “Double Down” recommendation in 2009 would have grown to $349,279.
– Apple: Investing $1,000 after the 2008 “Double Down” call would have resulted in a portfolio worth $48,196.
– Netflix: An initial $1,000 stake post the 2004 “Double Down” advice would have matured into $490,243.
Currently, the team is identifying three promising companies with the potential for significant growth, making it imperative not to overlook this unique opportunity. Further details on these “Double Down” stocks are available for review.
It is worth noting that the returns mentioned are based on Stock Advisor data up to December 16, 2024. It is important to exercise due diligence and consider various factors before making investment decisions. Personal financial advisor Prosper Junior Bakiny does not hold positions in the mentioned stocks. The Motley Fool acknowledges its positions in and recommends AbbVie and Abbott Laboratories while also endorsing Amgen, AstraZeneca Plc, and Novo Nordisk. The publication maintains a strict disclosure policy to ensure transparency and reliability for its readers.
